In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.</p
The adage that 'Time is Brain' remains a cornerstone of acute stroke treatment, and reflects the imp...
The global burden of stroke, the undisputed success of intravenous thrombolysis in the management of...
Item does not contain fulltextIntravenous thrombolysis (IVT) with recombinant tissue plasminogen act...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
Around 15 years have now elapsed since thrombolysis was first shown to be effective for treating acu...
Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the standard therapy...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
Over the past 50 years, thrombolytic agents have been devised with the aim of recanalizing occluded ...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
The first step in stroke care is early detection of stroke patients and recanalization of the occlud...
Thrombolysis with intravenous alteplase is the primary therapy for acute ischemic stroke, and is app...
Thrombolysis with intravenous alteplase is the primary therapy for acute ischemic stroke, and is app...
The adage that 'Time is Brain' remains a cornerstone of acute stroke treatment, and reflects the imp...
Introduction: The standard treatment for acute ischemic stroke is intravenous (IV) rtPA for patients...
The adage that 'Time is Brain' remains a cornerstone of acute stroke treatment, and reflects the imp...
The global burden of stroke, the undisputed success of intravenous thrombolysis in the management of...
Item does not contain fulltextIntravenous thrombolysis (IVT) with recombinant tissue plasminogen act...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
Around 15 years have now elapsed since thrombolysis was first shown to be effective for treating acu...
Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the standard therapy...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
Over the past 50 years, thrombolytic agents have been devised with the aim of recanalizing occluded ...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
The first step in stroke care is early detection of stroke patients and recanalization of the occlud...
Thrombolysis with intravenous alteplase is the primary therapy for acute ischemic stroke, and is app...
Thrombolysis with intravenous alteplase is the primary therapy for acute ischemic stroke, and is app...
The adage that 'Time is Brain' remains a cornerstone of acute stroke treatment, and reflects the imp...
Introduction: The standard treatment for acute ischemic stroke is intravenous (IV) rtPA for patients...
The adage that 'Time is Brain' remains a cornerstone of acute stroke treatment, and reflects the imp...
The global burden of stroke, the undisputed success of intravenous thrombolysis in the management of...
Item does not contain fulltextIntravenous thrombolysis (IVT) with recombinant tissue plasminogen act...